Voluntary PPA drug recall

WASHINGTON: Drug companies have moved to reassure consumers by voluntarily removing products containing phenylpropanolamine (PPA) from stores. This despite the fact that some believe the ingredient is not a risk when used correctly.

WASHINGTON: Drug companies have moved to reassure consumers by voluntarily removing products containing phenylpropanolamine (PPA) from stores. This despite the fact that some believe the ingredient is not a risk when used correctly.

WASHINGTON: Drug companies have moved to reassure consumers by voluntarily removing products containing phenylpropanolamine (PPA) from stores. This despite the fact that some believe the ingredient is not a risk when used correctly.

A health advisory issued by the FDA cited a study by Yale University School of Medicine, which found that PPA increases the risk of hemorrhagic stroke.

Ironically, the study was commissioned by the Consumer Healthcare Products Association (CHPA), which represents nonprescription drug manufacturers.

R. William Stoller, CHPA's SVP, said consumer safety is of primary importance, but that its members 'continue to support their product's safety.'

Bayer's Alka-Seltzer Plus, and Novartis' Triaminic DM are among the withdrawn products.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.